Revenue Performance - Revenue from mold fabrication in 2022 was HK706,025,000 in 2021[21] - Revenue from plastic components manufacturing in 2022 was HK1,698,373,000 in 2021[21] - Total revenue for 2022 was HK2,404,398,000 in 2021[21] - Revenue for 2022 was HK2,279.3 million, a year-on-year decrease of 5.2% compared to HK648.2 million, accounting for 28.4% of total revenue[82] - Medical and personal health care revenue increased by 3.6% to HK330.6 million, contributing 14.5% to total revenue[82] - Automobiles revenue declined by 33.5% to HK293.1 million, accounting for 12.9% of total revenue[82] - Mold fabrication segment revenue decreased by 14.1% to HK1,673.1 million, accounting for 73.4% of total revenue[91] - Total revenue for 2022 was HK1,673.1 million, accounting for 73.4% of total revenue[109] - Revenue from external customers of the plastic components manufacturing segment decreased by HK1,673.1 million in 2022 compared to HK99.8 million (14.1%) to HK706.0 million in 2021, affected by supply chain disruptions and semiconductor shortages[142] - Revenue for 2022 was HK125.1 million or 5.2% compared to 2021[188] - The company's revenue for the year ended December 31, 2022, was approximately HKD 2,279.3 million, a decrease of HKD 125.1 million or 5.2% compared to 2021[197] Profit and Profit Margins - Net profit for 2022 was HK200 million for the past four years[26] - Net profit margin remained above 10% despite challenging business conditions[26] - Profit for the year was HK226.9 million, a decrease of 19.6% from the previous year[67] - Net profit for the year dropped by 19.6% to HK226.9 million, a decrease of HK541.3 million, with gross profit margin remaining stable at 23.7%[84] - Gross profit margin for the mold fabrication segment decreased by 0.7 percentage points to 26.4%[106] - Gross profit margin for plastic components manufacturing increased by 0.6 percentage points to 22.8%[113] - Gross profit for 2022 was HK27.9 million (4.9%) from HK541.3 million, a decrease of HK924,579,000, up from HK924.6 million, maintaining a strong cash position[101] - The Group's net current assets as of 31 December 2022 were HK1,271.6 million, including HK1,605.6 million, with a gearing ratio of 21.6%, compared to HK1,605.6 million, with a debt-to-equity ratio of 21.6%, up from 20.9% in 2021[172] Dividends - The company proposed a final dividend of 8.6 HK cents per share, maintaining the same level as the previous year[31] - The dividend payout ratio for 2022 was 41.9%, with a total annual dividend of 11.4 HK cents per share[50] - The Board recommended a dividend payout ratio of 41.9%, with a final dividend of HK8.6 cents per share and a total dividend payout of HK11.4 cents per share for the year[67] Business Expansion and Strategy - The company expects recovery and rapid growth in 2023 as the impact of the epidemic dissipates[23] - The company has invested in new products and industries, exploring new business directions for sustainable growth[26] - The company established a production base in Vietnam to meet increasing demand and expand capacity[54] - The company is focusing on developing domestic leading enterprises to tap into the huge domestic demand market in China[54] - The company continues to seek suitable acquisition or investment targets to expand its business scope and industrial advantages[54] - The company maintains a strong focus on innovation and change, aiming to strengthen its position in the plastic injection molding industry chain[55] - The company aims to double the scale of its plastic injection molding business as part of its five-year plan set in 2020[70] - The company successfully entered the medical testing consumables and electronic atomizers industries, which have low seasonal and economic cyclical sensitivity[71] - The company has developed a product solution integrating liquid silicone and traditional plastic injection molding technology, improving product design, comfort, and functionality[71] - The company has established a production base in Vietnam and plans to expand capacity to meet increasing demand[56] - The company is focusing on developing domestic market opportunities in China and supporting Chinese brands in international markets[56] - The company is actively seeking acquisition or investment opportunities to expand its business and industry advantages[56] Segment Performance - Commercial telecommunications equipment segment revenue increased significantly by 72.1% year-on-year[111] - Electronic atomizers segment revenue grew by 27.0% year-on-year[111] - Smart home and medical & personal care segments saw steady revenue growth of 7.7% and 3.6% respectively[112] - The commercial communication equipment segment revenue increased significantly by 72.1% year-on-year, driven by successful customer business transformation and new product launches[138] - The smart home segment and medical/personal health care segment achieved stable revenue growth, with year-on-year increases of 7.7% and 3.6% respectively[195] Expenses and Other Financial Metrics - Administrative expenses for 2022 were HK7.3 million (14.0%) to HK51.9 million in 2021, mainly due to reduced sales of scrap and surplus materials[147] - Net finance income for 2022 decreased by HK13.4 million from HK$18.1 million in 2021, primarily due to increased interest expenses[131] - Trade receivable turnover days increased to 54 days in 2022, up 4 days from 2021, due to increased sales to domestic customers with credit periods of 60 to 90 days[160][165] - Trade payable turnover days decreased to 57 days in 2022, down 5 days from 2021, due to reduced procurement and lower trade payables balance[160][181] - The company's inventory turnover days remained unchanged at 98 days compared to 2021[200]
东江集团控股(02283) - 2022 - 年度财报